與抗體相關的合作與授權協議（2019-2026 年）

Antibody Collaboration and Licensing Deals 2019-2026

出版日期: 2026年05月01日 | 出版商:

Current Partnering | 英文 700+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗體交易的權威基準

本報告對全球抗體治療領域的合約趨勢進行了全面且以商業性觀點的分析。這將使業務拓展團隊能夠獲得關鍵訊息，從而在生物製藥合作這一最活躍、最有價值的領域之一中有效競爭。

本報告涵蓋了自 2019 年以來宣布的協議，提供了一個詳細而系統的抗體相關交易資料庫，包括藥物發現、開發和商業化各個階段的合作、許可協議和戰略夥伴關係。

調查範圍

本報告觀點了抗體領域的合作關係，結合詳細的交易數據和合約層面的見解，為循證決策提供支持。

範圍：

關於抗體藥物的合作與授權合約。
詳細的財務條款，包括預付款、里程碑付款和版稅。
如有揭露，則可查閱原始合約。
對各種抗體形式的合約結構進行分析，包括單株抗體、雙特異性抗體和抗體藥物複合體（ADC）。

主要特點：

對 2019 年以來抗體相關合約趨勢的全面分析。
確定最活躍和最具戰略意義的合約方。
對類似交易的財務狀況進行詳細基準分析
對合約結構進行詳細評估，包括權利分配和開發責任。
在有資訊披露的情況下，對關鍵合約條款進行合約層面的分析。
對抗體藥物偶聯物（ADC）作為快速成長的高附加價值合作領域進行重點分析。

本報告能夠達成的目標：

抗體和抗體偶聯藥物領域合約條款的可靠基準分析
識別並優先考慮高價值的合作機會
了解大型公司如何制定具有競爭力的合約
基於實際交易資料對合約前提條件檢驗
透過證據支持的資訊增強談判能力
透過存取組織良好、結構化的合約資料庫，顯著減少了研究時間。
在競爭激烈的市場中加速業務發展（BD）決策

本報告由以下幾個部分組成：

抗體相關合約摘要
抗體領域合作活動的趨勢
按合約價值分析暢銷合約
對抗體領域最活躍公司的分析
合約分析和合約結構的見解
按抗體技術類型（包括抗體藥物偶聯物）進行合約分析。

商業性意義：

抗體療法仍然是生物製藥合約的核心支柱，現有療法持續活躍，下一代療法發展勢頭強勁。
特別是抗體藥物複合體（ADC）已成為合作領域中最具競爭力和資本密集的領域之一，推動了高價值交易和策略聯盟的激增。
在這種環境下，獲取高品質的合約層面和合約情報至關重要。
本報告提供了進行有效基準測試、確定合適的合作夥伴以及更有信心地執行合約所需的見解，幫助您根據當今市場合約的實際結構和談判方法制定業務發展策略。

合約目錄
合約目錄：依公司名稱（A-Z）排列的抗體合約
合約目錄：依合約類型分類的抗體合約
合約目錄：按治療領域分類的抗體合約
合約類型的定義
關於 Biopharma Research Ltd.
關於當前合作夥伴關係
關於現行協議
Current Partnering 最新報告列表

簡介目錄

Product Code: CP2113

Antibody Collaboration and Licensing Deals

The Antibody Collaboration and Licensing Deals report delivers a comprehensive and commercially focused analysis of global dealmaking across antibody therapeutics - equipping business development teams with the critical intelligence required to compete effectively in one of the most active and high-value areas of biopharma partnering.

Covering deals announced since 2019, the report provides a detailed and structured database of antibody transactions spanning collaborations, licensing agreements, and strategic partnerships across discovery, development, and commercialization.

Report Scope

This report provides a complete and actionable view of the antibody partnering landscape, combining granular deal data with contract-level insight to support confident, evidence-based decision-making.

Coverage includes:

Collaboration and licensing deals across antibody therapeutics
Detailed financial terms including upfronts, milestones, and royalties
Access to underlying contract documents where disclosed
Analysis of deal structures across antibody formats, including monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs)
Key Features
Comprehensive analysis of antibody dealmaking activity and trends since 2019
Identification of the most active and strategically relevant dealmakers
Robust benchmarking of financial terms across comparable transactions
Detailed evaluation of deal structures, including rights allocation and development responsibilities
Contract-level insights into key clauses where disclosures are available
Focused analysis of ADCs as a rapidly expanding, high-value partnering segment driving deal activity
What This Report Enables You To Do
Benchmark antibody and ADC deal terms with confidence
Identify and prioritise high-value partnering opportunities
Understand how leading companies are structuring competitive deals
Validate deal assumptions using real-world transaction data
Strengthen negotiation positioning with evidence-backed insights
Save hundreds of hours of research time by accessing a fully curated, structured deal and contract dataset in one place
Accelerate BD decision-making in a fast-moving and competitive market
Report Structure

The report is organized into the following sections:

Overview of antibody dealmaking
Trends in antibody partnering activity
Analysis of leading deals by value
Most active companies in antibody dealmaking
Contract analysis and deal structure insights
Deal analysis by antibody technology type, including ADCs
Commercial Relevance
Antibody therapeutics remain a core pillar of biopharma dealmaking, with sustained activity across established modalities and accelerating momentum in next-generation formats.
In particular, antibody-drug conjugates (ADCs) have emerged as one of the most competitive and capital-intensive areas of partnering, driving a surge in high-value transactions and strategic collaborations.
In this environment, access to high-quality, deal-level and contract-level intelligence is essential.
This report provides the insight required to benchmark effectively, identify the right partners, and execute deals with greater confidence-ensuring your BD strategy is grounded in how transactions are actually being structured and negotiated in the market today.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

2.1. Introduction
2.2. Antibody deals over the years
2.3. Most active antibody dealmakers
2.4. Antibody deals by deal type
2.5. Antibody deals by therapy area
2.6. Antibody deals by industry sector
2.7. Deal terms for antibody deals
- 2.7.1 Antibody deals headline values
- 2.7.2 Antibody deal upfront payments
- 2.7.3 Antibody deal milestone payments
- 2.7.4 Antibody royalty rates